ExpreS2ion Biotechnologies – Nipah-vaccine project illustrates strength of platform and how the company can move on from the lost Covid-19 opportunity
On Thursday, we held an event with Expre2sion Biotechnologies following the announcement of a new exciting Nipah-vaccine project. At the event CEO Bent Frandsen presented the company's ExpreS2-platform and Adaptvac’s VLP technology. This unique technology platform is used for several projects in the company’s broad pipeline. In contrast to many other Life Science companies in their developing phase, ExpreS2ion Biotechnologies has already obtained a validation of its technology in connection with the completion of ABNCov2 phase 3 trial with Bavarian Nordic.
The unique technology platform also forms the basis for the recently announced Nipah virus project. It also includes the clinical team and partners. The Nipah-vaccine project is fully funded up to and including Phase 1. WHO characterizes the Nipah-disease as an extremely serious disease. It is hosted by bats and can be transmitted from bats to humans in which case it has a fatality rate of 40 to 75% with epidemic character and where there is currently no treatment. With the WHO label on the disease, a vaccine has a lot of focus from both the public and private markets. It also involves the risk of Nipah-virus being used in connection with bioterrorism which means many countries will consider building a strategic stock of vaccine once available. Generally, Expre2sion Biotechnologies’ commercialization strategy is to find a partner or finance a phase 2 development with its own funds or non-dilutive funding.
Listen to the interview here: Expre2sion Biotechnologies
Disclaimer: HC Andersen Capital receives payment from Expre2sion Biotechnologies for a DigitalIR/Corporate Visibility agreement.
Sisäänkirjautuminen vaadittu
Tämä sisältö on näkyvissä vain sisäänkirjautuneille käyttäjille
ExpreS2ion Biotech Holding
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Lue lisää yhtiösivulla